Sanofi $SNY Shares Purchased by Virtu Financial LLC

Virtu Financial LLC grew its position in Sanofi (NASDAQ:SNY) by 212.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 31,550 shares of the company’s stock after purchasing an additional 21,466 shares during the period. Virtu Financial LLC’s holdings in Sanofi were worth $1,529,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in SNY. Flagship Harbor Advisors LLC acquired a new position in shares of Sanofi during the fourth quarter worth approximately $25,000. Measured Wealth Private Client Group LLC bought a new position in Sanofi in the 3rd quarter worth approximately $29,000. Palisade Asset Management LLC acquired a new stake in Sanofi in the 3rd quarter valued at approximately $30,000. Annis Gardner Whiting Capital Advisors LLC increased its position in Sanofi by 544.4% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock valued at $34,000 after acquiring an additional 588 shares during the period. Finally, Larson Financial Group LLC raised its stake in Sanofi by 48.9% during the 4th quarter. Larson Financial Group LLC now owns 810 shares of the company’s stock valued at $39,000 after acquiring an additional 266 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on SNY shares. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Finally, BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Hold” and a consensus target price of $51.00.

Sanofi Price Performance

SNY opened at $42.38 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. The company has a market capitalization of $102.75 billion, a PE ratio of 11.84, a P/E/G ratio of 1.04 and a beta of 0.34. The stock’s fifty day moving average is $44.70 and its 200-day moving average is $46.31. Sanofi has a one year low of $41.85 and a one year high of $52.68.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were issued a $2.4225 dividend. This represents a dividend yield of 559.0%. The ex-dividend date was Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s payout ratio is presently 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.